A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
Status: Recruiting
Location: See all (7) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
• Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
• Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Locations
United States
Pennsylvania
Perelman Center for Advanced Medicine - Endocrinology
RECRUITING
Philadelphia
Montefiore Clinical and Translational Research Center - Endocrinology
RECRUITING
Pittsburgh
Wisconsin
UW University Hospital - Endocrinology
RECRUITING
Madison
Other Locations
Canada
Toronto General Hospital - Endocrinology
RECRUITING
Toronto
Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre
RECRUITING
Vancouver
Saudi Arabia
King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology
RECRUITING
Riyadh
King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology
RECRUITING
Riyadh
Contact Information
Primary
Medical Information
medicalinfo@vrtx.com
617-341-6777
Time Frame
Start Date: 2025-03-31
Estimated Completion Date: 2027-09-17
Participants
Target number of participants: 10
Treatments
Experimental: VX-880
Related Therapeutic Areas
Sponsors
Leads: Vertex Pharmaceuticals Incorporated